InVivo Therapeutics Holdings Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVIV research report →
Companywww.invivotherapeutics.com
InVivo Therapeutics Holdings Corp. , a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI.
- CEO
- Richard M. Toselli
- IPO
- 2010
- Employees
- 6
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $995.92K
- P/E
- -0.05
- P/S
- 0.00
- P/B
- 0.03
- EV/EBITDA
- 1.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.12%
- ROIC
- -63.58%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-10,179,000 · -2.90%
- EPS
- $-6.62 · 11.38%
- Op Income
- $-10,650,000
- FCF YoY
- -19.16%
Performance & Tape
- 52W High
- $2.40
- 52W Low
- $0.22
- 50D MA
- $0.70
- 200D MA
- $1.05
- Beta
- 0.66
- Avg Volume
- 3.77M
Get TickerSpark's AI analysis on NVIV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 5, 23 | Foose Brice | sell | 37,000 |
| Feb 5, 23 | Foose Brice | sell | 20,000 |
| Feb 5, 23 | Foose Brice | sell | 13,000 |
| Feb 5, 23 | Foose Brice | sell | 48,000 |
| Feb 5, 23 | Foose Brice | sell | 12,000 |
| Feb 5, 23 | Foose Brice | sell | 36,000 |
| Feb 6, 23 | Foose Brice | sell | 8,000 |
| Feb 6, 23 | Foose Brice | sell | 33,000 |
| Feb 6, 23 | Foose Brice | sell | 35,000 |
| Feb 6, 23 | Foose Brice | sell | 37,000 |
Our NVIV Coverage
We haven't published any research on NVIV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVIV Report →